Study Type
Observational
completed
The aims of the EFAS pilot study were:
- To characterize early effects of Roux-en-Y surgery on liver fat content in obese patients with type 2 diabetes
- To study the associations between liver fat content and glycemic parameters during perioperative period
- To assess the feasibility of recruiting study subjects and performing MRI imaging in this patient population.
Primary outcome:
Change in AUC glucose 0-150min from 0 to 4 weeks.
Mehran Anvari was Co-Principal Investigator on the EFAS study with Hertzel Gerstein.
Study Design
Cohort pilot
NO. of Countries
1
NO. of Sites
1
NO. of Participants
18
Study Period
2014-2015
Sponsor
PHRI
Hertzel Gerstein
Interim Executive Director; Senior Scientist
Hertzel Gerstein
Interim Executive Director; Senior Scientist
Hertzel Gerstein is PHRI’s Interim Executive Director and Senior Lead of the Diabetes Scientific Program. He is also a Professor of Medicine at McMaster University where he holds the Population Health Research Institute Chair in Diabetes; an Endocrinologist; Director of the Boris Clinic Diabetes Care and Research Program; Chair of Diabetes Clinical Trials Network Canada; and a Fellow of both the Canadian Academy of Health Sciences and the Royal Society of Canada.
Gerstein pioneered and firmly established international long-term diabetes-focused outcomes trials as the norm to support Evidence-Based Diabetes Care. Randomized trials that he designed and led have collectively included more than 90,000 people with either diabetes or prediabetes to date, and have studied and identified clinically important, life-saving diabetes therapies. These trials were supported by the US National Institute of Health, the Canadian Institutes of Health Research, other Canadian peer-review agencies, and by industry. Together, they have substantially expanded the evidence-base pertaining to the prevention, remission, and treatment of diabetes and its consequences, and some of their findings have provided the evidence base for international diabetes guidelines and novel drug indications that have improved the lives of people living with diabetes or prediabetes.
His research has been published in over 600 papers and his h index is 100. His work has been recognized by many awards, including the 2012 Canadian Diabetes Association’s Lifetime Achievement Award and the 2022 American Diabetes Association’s Outstanding Achievement in Clinical Diabetes Research Award.
Natalia McInnes
Investigator
Natalia McInnes
Investigator
Natalia McInnes is the Joint Principal Investigator for the Diabetes Remission program at PHRI, and Assistant Professor in the Division of Endocrinology, McMaster University. She has received peer-reviewed research funding from CIHR and Canadian Diabetes Association and is supported by the Medicine Internal Career Award from McMaster University. Her research interests include remission of pre-diabetes and type 2 diabetes, and the relationship between dysglycemia and ectopic fat deposition.
She received her medical degree from the University of British Columbia. After completing her Internal Medicine and Endocrinology training, she pursued MSc in Health Research Methodology at McMaster University.
Tara McCready
Program Director
Tara McCready
Program Director
Tara McCready, PhD, oversees a variety of collaborative programs at PHRI, and serves as Project Manager for PHRI research studies and registries.
She was recruited to PHRI as a Program Director for the Canadian Network and Centre for Trials Internationally (CANNeCTIN), a national network funded by the CIHR/CFI Clinical Research Initiative program to improve the prevention and treatment of cardiac and vascular diseases and diabetes.
Previously the Executive Director of the Canadian Maternal, Infant, Child and Youth Research Network, Tara holds a PhD in Biochemistry and a MBA in Technology Commercialization from the University of Alberta.
